Cetera Investment Advisers Buys 65,526 Shares of Elanco Animal Health Incorporated $ELAN

Key Points

• Cetera Investment Advisers more than doubled its Elanco position in the first quarter, acquiring 65,526 additional shares for a total of 121,502 shares valued at approximately $2.9 million.
• Elanco beat second-quarter expectations, reporting adjusted EPS of $0.34 and revenue of $1.368 billion, up 10.2% year over year. Management raised its full-year 2026 EPS, revenue and adjusted EBITDA guidance, citing momentum in newer products such as Zenrelia.
• Analyst sentiment remains broadly positive, with UBS and other brokerages raising price targets; MarketBeat reports a consensus “Moderate Buy” rating and a $29.09 target price. Institutional investors own 97.48% of Elanco’s shares.

Cetera Investment Advisers grew its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 117.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 121,502 shares of the company's stock after acquiring an additional 65,526 shares during the quarter. Cetera Investment Advisers' holdings in Elanco Animal Health were worth $2,908,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Parallel Advisors LLC grew its position in Elanco Animal Health by 5.9% in the 4th quarter. Parallel Advisors LLC now owns 7,060 shares of the company's stock worth $160,000 after purchasing an additional 392 shares in the last quarter. Lazard Asset Management LLC lifted its holdings in Elanco Animal Health by 0.6% during the fourth quarter. Lazard Asset Management LLC now owns 72,065 shares of the company's stock worth $1,631,000 after acquiring an additional 425 shares during the period. Northwestern Mutual Investment Management Company LLC boosted its position in Elanco Animal Health by 0.4% in the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 111,166 shares of the company's stock worth $2,516,000 after purchasing an additional 428 shares during the last quarter. Meeder Advisory Services Inc. boosted its position in Elanco Animal Health by 4.8% in the fourth quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company's stock worth $254,000 after purchasing an additional 510 shares during the last quarter. Finally, Bessemer Group Inc. boosted its position in Elanco Animal Health by 33.2% in the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company's stock worth $50,000 after purchasing an additional 525 shares during the last quarter. Institutional investors own 97.48% of the company's stock.

Elanco Animal Health News Roundup

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Elanco beat estimates with second-quarter adjusted EPS of $0.34 versus the $0.27 consensus, while revenue rose 10.2% year over year to $1.368 billion, exceeding estimates of $1.31 billion. Elanco Animal Health Reports Second Quarter 2026 Results
• Positive Sentiment: The company raised its full-year 2026 adjusted EPS outlook to $1.10-$1.16 from prior expectations near $1.07, increased revenue guidance to $5.09-$5.14 billion, and lifted its adjusted EBITDA forecast to $1.01-$1.035 billion. It also raised its innovation-revenue target to $1.25 billion. Elanco Lifts Outlook as 2Q Profit, Revenue Rise
• Positive Sentiment: Management cited continued momentum in newer products, with allergy treatment Zenrelia reaching blockbuster status. CEO Jeff Simmons also pointed to increased tick-bite activity and ongoing consumer spending on pet-health products as supportive demand trends. Elanco CEO on Boosted Forecast, Surge in Tick Bites
• Positive Sentiment: Analyst sentiment improved after the earnings report: UBS raised its price target from $31 to $33 and assigned a Buy rating, while KeyCorp increased its target from $29 to $30 and maintained an Overweight rating.
• Neutral Sentiment: Third-quarter guidance calls for adjusted EPS of $0.19-$0.22 and revenue of approximately $1.2 billion. The EPS range is broadly in line with consensus, so it offers limited near-term upside relative to the stronger full-year outlook.
• Negative Sentiment: Elanco remains leveraged, although management improved its year-end net-leverage target to approximately 3.0 times adjusted EBITDA from 3.1 times at the end of the second quarter. Reported net income was $54 million, and the company continues to post a negative reported net margin.

Analyst Ratings Changes

Several brokerages have recently issued reports on ELAN. Wall Street Zen lowered Elanco Animal Health from a "strong-buy" rating to a "buy" rating in a research report on Sunday, May 24th. UBS Group boosted their price target on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a "buy" rating in a report on Thursday. Weiss Ratings upgraded shares of Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a research report on Friday, July 31st. TD Cowen increased their price target on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a "buy" rating in a research report on Thursday, June 18th. Finally, Citigroup raised their price objective on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a "buy" rating in a report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $29.09.

Elanco Animal Health Price Performance

Shares of NYSE:ELAN opened at $24.23 on Friday. The firm has a market capitalization of $12.10 billion, a PE ratio of -59.09, a P/E/G ratio of 1.73 and a beta of 1.67. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60. The company has a 50-day moving average price of $24.73 and a two-hundred day moving average price of $24.10. Elanco Animal Health Incorporated has a twelve month low of $15.50 and a twelve month high of $27.98.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.07. The company had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.12%. The company's quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Equities analysts forecast that Elanco Animal Health Incorporated will post 1.1 EPS for the current year.

Insider Buying and Selling

In other Elanco Animal Health news, CEO Jeffrey N. Simmons bought 4,971 shares of the stock in a transaction on Friday, May 15th. The shares were acquired at an average price of $20.09 per share, with a total value of $99,867.39. Following the acquisition, the chief executive officer directly owned 171,971 shares of the company's stock, valued at $3,454,897.39. The trade was a 2.98% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Rajeev A. Modi bought 4,911 shares of the stock in a transaction on Friday, May 15th. The shares were acquired at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the acquisition, the insider directly owned 160,812 shares in the company, valued at approximately $3,272,524.20. This trade represents a 3.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 1.14% of the stock is currently owned by insiders.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source